| Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment (NCT03941587) | Singapore National Eye Centre | 2021-02-01 |
| Clinical Implication of Aflibercept in PCV Treatment in China (NCT05639660) | Peking Union Medical College Hospital | 2021-01-01 |
| Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept (NCT04707027) | Chiang Mai University | 2020-11-01 |
| Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy (NCT04380974) | Xiaodong Sun | 2020-06-01 |
| Biomarkers of Common Eye Diseases (NCT04101604) | Sun Yat-sen University | 2019-09-26 |
| Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV) (NCT03929731) | Singapore National Eye Centre | 2019-07-05 |
| OCTA and Polypoidal Choroidal Vasculopathy (NCT04714242) | Federico II University | 2019-01-15 |
| Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy (NCT02769169) | Sun Yat-sen University | 2018-08-01 |
| Conbercept for Polypoidal Choroidal Vasculopathy（START Study） (NCT05229237) | Peking Union Medical College Hospital | 2018-05-01 |
| An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy (NCT03117634) | Singapore National Eye Centre | 2017-12-01 |
| Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases (NCT03128463) | Xun Xu | 2017-02-28 |
| Initial Versus Delayed PDT Combination With Conbercept in PCV (NCT02821520) | The Eye Hospital of Wenzhou Medical University | 2017-01-01 |
| Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy (NCT02976194) | Pusan National University Hospital | 2016-11-22 |
| Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers (NCT02815176) | Samsung Medical Center | 2016-06-01 |
| Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy (NCT02495181) | Association for Innovation and Biomedical Research on Light and Image | 2015-11-23 |
| Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy (NCT02597855) | Yeungnam University College of Medicine | 2015-09-01 |
| OCT in Rare Chorioretinal Diseases (NCT02141308) | Oregon Health and Science University | 2014-05-01 |
| Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment (NCT02381730) | Fondation Ophtalmologique Adolphe de Rothschild | 2014-01-01 |
| Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy (NCT01950741) | Pusan National University Hospital | 2013-09-01 |
| Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) (NCT01846273) | Novartis Pharmaceuticals | 2013-08-07 |
| Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation (NCT01871376) | Gregg T. Kokame, MD | 2013-05-01 |
| Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen (NCT03459144) | Sun Yat-sen University | 2012-12-01 |
| Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy (NCT01469156) | Southeast Retina Center, Georgia | 2011-09-01 |
| Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy (NCT01360151) | Seoul St. Mary's Hospital | 2011-02-01 |
| Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) (NCT01884597) | Hawaii Pacific Health | 2010-11-01 |
| Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy (NCT01248117) | Retina Consultants of Hawaii | 2010-11-01 |
| Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV) (NCT01023295) | Mateon Therapeutics | 2009-07-01 |
| Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs (NCT01271426) | Nihon University | 2008-04-01 |
| Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy (NCT00674323) | Novartis | 2008-04-01 |
| Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy (NCT00470977) | Manhattan Eye, Ear & Throat Hospital | 2007-05-01 |
| Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) (NCT00424710) | Hawaii Pacific Health | 2007-01-01 |
| Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy (NCT00344617) | Singapore National Eye Centre | 2006-06-01 |
| Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy (NCT00837330) | Southeast Retina Center, Georgia | 2006-05-01 |
| Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy (NCT00383812) | Asan Medical Center | 2006-05-01 |